Vitamin Supplementation in the Treatment of Schizophrenia

Brown, Henry Phelps; Roffman, Joshua L.

doi:10.1007/s40263-014-0172-4

Cited by 51 publications

(27 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, it is worth mentioning in this review that many of the emerging alternative treatments proposed for SZ [e.g., vitamins (Arroll et al, 2014; Brown and Roffman, 2014), omega-3 fatty acids (Hashimoto et al, 2014), anti-inflammatory agents (Girgis et al, 2014)] can have direct and/or indirect impacts on inflammatory status, membrane lipids profiles, and membrane structural properties (Yaqoob and Shaikh, 2010). Omega-3 fatty acids in particular have important effects on brain functions since docosahexaenoic acid (DHA) is a major structural component of phospholipids in neuronal cell membranes and eicosapentaenoic acid (EPA) shows neurotransmitter and neuromodulatory activity (Fenton et al, 2000) which may have therapeutic properties in psychotic symptoms.…”

Section: Schizophrenia and Sphingolipidsmentioning

confidence: 99%

From Molecules to the Clinic: Linking Schizophrenia and Metabolic Syndrome through Sphingolipids Metabolism

et al. 2016

View full text Add to dashboard Cite

Metabolic syndrome (MS) is a prevalent and severe comorbidity observed in schizophrenia (SZ). The exact nature of this association is controversial and very often accredited to the effects of psychotropic medications and disease-induced life-style modifications, such as inactive lifestyle, poor dietary choices, and smoking. However, drug therapy and disease-induced lifestyle factors are likely not the only factors contributing to the observed converging nature of these conditions, since an increased prevalence of MS is also observed in first episode and drug-naïve psychosis populations. MS and SZ share common intrinsic susceptibility factors and etiopathogenic mechanisms, which may change the way we approach clinical management of SZ patients. Among the most relevant common pathogenic pathways of SZ and MS are alterations in the sphingolipids (SLs) metabolism and SLs homeostasis. SLs have important structural functions as they participate in the formation of membrane “lipid rafts.” SLs also play physiological roles in cell differentiation, proliferation, and inflammatory processes, which might be part of MS/SZ common pathophysiological processes. In this article we review a plausible mechanism to explain the link between MS and SZ through a disruption in SL homeostasis. Additionally, we provide insights on how this hypothesis can lead to the developing of new diagnostic/therapeutic technologies for SZ patients.

show abstract

Section: Schizophrenia and Sphingolipidsmentioning

confidence: 99%

From Molecules to the Clinic: Linking Schizophrenia and Metabolic Syndrome through Sphingolipids Metabolism

et al. 2016

View full text Add to dashboard Cite

show abstract

“…7 According to our results, in addition to those conventional functions, aripiprazole may have accessional positive effects on schizophrenic patients through elevating vitamin D concentrations and ameliorating vitamin D deficiency. Given that vitamin D supplementation may play an important role in the treatment of schizophrenia, 39,40 this would be an exciting finding for clinical practice. However, we failed to find associations between other atypical antipsychotics and vitamin D concentrations, suggesting that more attention should be paid to patients taking these atypical antipsychotics to avoid hypovitaminosis D. There was a possibility that increasing vitamin D concentrations arise from healthier lifestyles due to the controlled symptoms of schizophrenia.…”

Section: Discussionmentioning

confidence: 99%

Effects of Atypical Antipsychotics on Neuroactive Vitamins in Patients With Schizophrenia

Yuan

Wang

et al. 2020

The Journal of Clinical Pharma

View full text Add to dashboard Cite

In schizophrenia, neuroactive vitamins A/D/E play vital neuroprotective roles in its pathophysiological processes. During medical treatment, atypical antipsychotics, including aripiprazole, amisulpride, olanzapine, and paliperidone, were widely used at present. However, their impact on vitamin metabolism in vivo remained unclear. In this study, we conducted a case‐control research to investigate the impacts of antipsychotics on vitamin metabolism. Schizophrenic patients (n = 163), who were divided into 5 groups (aripiprazole group, amisulpride group, olanzapine group, paliperidone group, nonmedication group) according to their different medication patterns, and healthy controls (n = 75) were involved. The concentrations of vitamin A/D/E and antipsychotics were measured using liquid chromatography–tandem mass spectrometry methods. Compared with healthy controls, significantly lower vitamin D and E concentrations were found in the nonmedication group after covariance analysis adjusting for age, sex, albumin, bilirubin, triglyceride, and cholesterol. We found that aripiprazole could affect vitamin D concentrations in vivo, and a positive correlation between aripiprazole concentrations and vitamin D concentrations (r = 0.319, P = 0.025) was observed in aripiprazole group. Such result revealed the very first observation for the influence of atypical antipsychotics medication toward vitamin status in vivo. Our study showed that low concentrations of vitamin D and E in vivo could be associated with schizophrenia, suggesting that hypovitaminosis may lead to a vulnerability to schizophrenia. More importantly, aripiprazole may potentially benefit the patients through improving their vitamin D status in vivo.

show abstract

“…As mentioned in Table 1, the administration of folic acid supplements may help ameliorate positive and negative symptoms in schizophrenia. Vitamin C, E, and B (including B12 and B6) were also found to be effective in managing schizophrenia symptoms (Brown & Roffman, 2014). The administration of vitamin D helps improve daily living (Cieslak et al, 2014), as mentioned in Table 1.…”

Section: Complementary Intervention and Dietmentioning

confidence: 99%

A Survey Towards Holistic Management of Schizophrenia

Ganguly¹,

Moustafa²

2018

JPR

View full text Add to dashboard Cite

Holistic management of schizophrenia involves main stream pharmacological intervention, complimentary medicine intervention, therapeutic intervention, and other psychosocial factors, such as accommodation, education, job training, employment, relationship, friendship, exercise, overall well-being, smoking, substance abuse, suicide prevention, stigmatisation, recreation, entertainment, violent behaviour, arrangement of public trusteeship and guardianship, day-day-living skill, integration with community, management of overweight due to medications, and other health complications related to medications amongst others. Our review shows that there is no integrated survey by combining all these factors. We are conducting an international web based survey to evaluate the significance of all these factors and present them in a unified manner. We believe this investigation will contribute positively towards holistic management of schizophrenia. There will be two surveys. In the pharmacological intervention survey, five popular drugs for schizophrenia will be chosen and their efficacy as well as harmful side effects will be evaluated in a scale of 0-10. This survey will be done by psychiatrists. In the second survey, each element of therapeutic intervention and psychosocial factors will be evaluated according to their significance in a scale of 0-10. This survey will be done by care givers, psychologists, case managers, and case workers. For the first survey, we will contact the professional bodies of the psychiatrists in English speaking countries and request them to ask their members to participate in the survey. For the second survey, we will contact the professional bodies of clinical psychologist and care givers in English speaking countries and request them to ask their members to participate in the survey. Additionally for both the surveys, we will contact the relevant professionals through personal contact networks. For both the surveys, mean, mode, median, standard deviation, and net promoter score will be calculated for each factor and presented then in a statistically significant manner. Subsequently, each factor will be ranked according to their statistical significance. Additionally, country specific variation will be highlighted to identify the variation pattern. The results of these surveys will identify the relative significance of each type of pharmacological intervention, each type of therapeutic intervention, and each type of psychosocial factor. The determination of this relative importance will definitely contribute to the improvement in quality of life for individuals with schizophrenia.

show abstract

Vitamin Supplementation in the Treatment of Schizophrenia

Cited by 51 publications

References 42 publications

From Molecules to the Clinic: Linking Schizophrenia and Metabolic Syndrome through Sphingolipids Metabolism

From Molecules to the Clinic: Linking Schizophrenia and Metabolic Syndrome through Sphingolipids Metabolism

Effects of Atypical Antipsychotics on Neuroactive Vitamins in Patients With Schizophrenia

A Survey Towards Holistic Management of Schizophrenia

Contact Info

Product

Resources

About